We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.57B
AUM Growth
-$21.5M
Cap. Flow
+$32.3M
Cap. Flow %
1.25%
Top 10 Hldgs %
39.02%
Holding
197
New
37
Increased
49
Reduced
41
Closed
10

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$39M
2
JNJ icon
Johnson & Johnson
JNJ
+$21.2M
3
ESPR
Esperion Therapeutics
ESPR
+$13.9M
4
ABBV icon
AbbVie
ABBV
+$11.5M
5
BMY icon
Bristol-Myers Squibb
BMY
+$11.4M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$36.3M
2
AMGN icon
Amgen
AMGN
+$29.7M
3
BIIB icon
Biogen
BIIB
+$20.8M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$19.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 93.47%
2 Real Estate 2.71%
3 Financials 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNC icon
26
Centene
CNC
$30.1B
$24.6M 0.96%
460,316
– –
NBIX icon
27
Neurocrine Biosciences
NBIX
$18.7B
$23.2M 0.9%
279,419
-45,648
-14% -$3.85M
CVS icon
28
CVS Health
CVS
$134B
$22.8M 0.89%
366,521
– –
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$11.7B
$22.8M 0.89%
281,076
-208,669
-43% -$17.9M
XBI icon
30
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$22M 0.85%
250,460
+24,000
+11% +$2.19M
ELV icon
31
Elevance Health
ELV
$81.6B
$20.1M 0.78%
91,482
+46,564
+104% +$10.9M
SAGE
32
DELISTED
Sage Therapeutics
SAGE
$20.1M 0.78%
124,650
+56,835
+84% +$9.65M
TEVA icon
33
Teva Pharmaceuticals
TEVA
$41.2B
$18.5M 0.72%
1,083,223
-499,885
-32% -$9.76M
JAZZ icon
34
Jazz Pharmaceuticals
JAZZ
$16.2B
$18.5M 0.72%
122,482
+24,061
+24% +$3.53M
SGEN
35
DELISTED
Seagen Inc. Common Stock
SGEN
$18.1M 0.71%
346,499
+122,799
+55% +$6.69M
SHPG
36
DELISTED
Shire pic
SHPG
$17.3M 0.67%
115,629
-86,110
-43% -$11.9M
OHI icon
37
Omega Healthcare
OHI
$15B
$15.7M 0.61%
579,785
– –
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$27.4B
$15.5M 0.6%
130,376
+15,410
+13% +$1.99M
AZN icon
39
AstraZeneca
AZN
$266B
$15.5M 0.6%
221,300
– –
GSK icon
40
GSK
GSK
$104B
$15.4M 0.6%
315,799
+28,599
+10% +$1.33M
PVLA
41
Palvella Therapeutics
PVLA
$2.15B
$14.2M 0.55%
26,092
+1,562
+6% +$967K
MCK icon
42
McKesson
MCK
$101B
$13.9M 0.54%
98,797
-25,153
-20% -$3.92M
ESPR
43
DELISTED
Esperion Therapeutics
ESPR
$13.7M 0.53%
+189,287
New +$13.9M
NKTR icon
44
Nektar Therapeutics
NKTR
$2.41B
$13.2M 0.51%
+8,301
New +$10.7M
FOLD
45
DELISTED
Amicus Therapeutics
FOLD
$13.2M 0.51%
875,304
+270,384
+45% +$4.11M
SBRA icon
46
Sabra Healthcare REIT
SBRA
$5.38B
$12.8M 0.5%
724,606
– –
BSX icon
47
Boston Scientific
BSX
$68.4B
$12.5M 0.49%
457,585
+192,985
+73% +$5.25M
GWPH
48
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$12.5M 0.49%
110,784
+85,784
+343% +$10.8M
ALKS icon
49
Alkermes
ALKS
$8.39B
$12.2M 0.47%
210,182
+66,110
+46% +$3.87M
BLUE
50
DELISTED
bluebird bio
BLUE
$11.3M 0.44%
5,119
+1,483
+41% +$3.77M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Tekla Capital Management held 197 positions worth $2.57B, down 0.83% from $2.59B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management's Q1 2018 filing shows 37 new, 49 increased, 41 reduced and 10 closed positions. Its largest new stake was Esperion Therapeutics: 189,287 shares worth $13.7M. The largest sale was Gilead Sciences, an estimated $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 93% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q1 2018 buy was Esperion Therapeutics: 189,287 shares worth $13.7M.
  • Tekla Capital Management added most to Pfizer in Q1 2018, an estimated $39M increase.
  • Tekla Capital Management's biggest Q1 2018 reduction was Gilead Sciences, cutting an estimated $36.3M.
  • Tekla Capital Management fully exited NuVasive, Inc. in Q1 2018, selling an estimated $6.87M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.57B portfolio in Q1 2018.
  • Tekla Capital Management opened 37 new positions and closed 10 in Q1 2018.
  • Tekla Capital Management's portfolio value fell 0.83% quarter-over-quarter to $2.57B.

Based on Tekla Capital Management's 13F filing for Q1 2018, filed 14 May 2018.